Financing channel feed – Endpoints News

Financing channel feed

Jounce’s Cinderella story now includes a $102M IPO chapter

9 years ago

Singapore investors at Temasek grab an $800M stake in Google’s Verily

9 years ago

Venrock stocks up on $450M Fund 8 as it prepares a new string of biotech deals

9 years ago

An early arrival among '17 biotech IPOs, AnaptysBio keeps to its range in successful $75M play

9 years ago

Vision or voodoo? Biotech IPO master Vivek Ramaswamy is still setting up new biotechs and hatching more deals

9 years ago

The forecast for biotech IPOs in 2017? Not nearly as hot as the industry would like

9 years ago

Eli Lilly, Novartis back a $26M round for Cavion’s work on neurological diseases

9 years ago

Neon Therapeutics bags a $70M round for early-stage neoantigen research

9 years ago

Digitalis makes its debut with $100M fund and a yen for ‘deeply technical people’

9 years ago

Biotech backer Versant arms itself with record $400M fund, targets a new wave of upstarts

9 years ago

Chinese VC syndicates wager $172M on Ascentage and Ascletis, flagging a new trend

9 years ago

Jounce rings out the old year with a $75M IPO bid for the New Year

9 years ago

Celgene, Versant back a biotech merger, building an antibody pipeline and lining up for the clinic

9 years ago

TiGenix’s second stab at an IPO bags $36M for late-stage stem cell plans

9 years ago

Flagship takes on a pioneering new fund — and name — adding $285M to advance its startup mission

9 years ago

New York gambles $1.15B in new funds and incentives in search of a biotech jackpot

9 years ago

Section 32: Ex-Google venture chief Maris pursues indie role with $230M biotech fund

9 years ago

Biogen vet Adam Koppel is raising cash for a new life sciences fund at Bain Capital

9 years ago

GSK vet Jason Gardner takes the helm of Magenta, emerging from stealth with a $48.5M round

9 years ago

Syncona, CRUK and BACIT join forces to create a $1.2B biotech investment powerhouse

9 years ago

Influential Third Rock Ventures marks a decade of high-profile wins and losses with record $616M Fund IV

9 years ago

Turning pharma castoffs into an instant fortune, Vivek Ramaswamy’s Myovant bags a $218M IPO

9 years ago

Gene editing loses its sizzle. CRISPR Therapeutics IPO debuts beneath the range

9 years ago

Nancy Stagliano bags another $45M for True North’s rare disease R&D

9 years ago

First page Previous page 141 142 143144145 Next page Last page